The Lobos’ home arena, aptly named The Pit, is considered one of the tougher arenas to visit in the Mountain West — last week ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Salesforce has given $1 million to College Possible, the national nonprofit promoting college access by students from ...

Gaining More Approvals Lilly's GLP-1 drugs are showing no signs of slowing down. They have also proven to be superior to Novo ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

The Nigerian Institute of Public Relations (NIPR) has said that Nigeria needs effective leadership to overcome its current socioeconomic challenges. The NIPR President, Dr Ike Neliaku, in his New ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

placebo-controlled SURMOUNT-1 trial (ClinicalTrials.gov Identifier: NCT04184622) from December 2019 to July 2024. Participants were randomly assigned to receive 5, 10, or 15 mg tirzepatide or placebo.

The Phase IIIb SURMOUNT-5 trial found that Eli Lilly’s Zepbound was more effective in promoting weight loss than Novo Nordisk’s Wegovy. Credit: Ciara Kimsey / Shutterstock. Following positive results ...

China’s official Manufacturing Purchasing Managers' Index (PMI) eased to 50.1 in December, compared to 50.3 in the previous reading. The reading came in below the market consensus of 50.3 in the ...